# Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy

> **NCT04579133** · PHASE2 · TERMINATED · sponsor: **Latin American Cooperative Oncology Group** · enrollment: 140 (actual)

## Conditions studied

- Bladder Cancer
- Urothelial Carcinoma

## Interventions

- **DRUG:** Olaparib
- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT04579133
- **Lead sponsor:** Latin American Cooperative Oncology Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-03-01
- **Primary completion:** 2021-03-01
- **Final completion:** 2021-03-01
- **Target enrollment:** 140 (ACTUAL)
- **Why stopped:** Not approved
- **Last updated:** 2021-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04579133

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04579133, "Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04579133. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*